The State of Texas Top Legal Officer Sues Tylenol Producers Over Autism Allegations

Legal Action
Ken Paxton, who supports former President Trump campaigning for the United States Senate, accused the drug companies of hiding potential dangers of acetaminophen

The top legal official in Texas Paxton is taking legal action against the makers of acetaminophen, alleging the companies withheld alleged dangers that the pain reliever presented to children's neurological development.

The lawsuit arrives a month after President Donald Trump publicized an unverified association between consuming Tylenol - alternatively called paracetamol - throughout gestation and autism in offspring.

Paxton is taking legal action against J&J, which formerly manufactured the medication, the exclusive pain medication recommended for expectant mothers, and Kenvue, which presently makes it.

In a official comment, he said they "betrayed America by gaining financially from discomfort and pushing pills regardless of the dangers."

Kenvue says there is insufficient reliable data tying acetaminophen to autism.

"These companies misled for generations, intentionally threatening numerous people to line their pockets," Paxton, a Republican, said.

The manufacturer said in a statement that it was "very worried by the dissemination of inaccurate information on the safety of acetaminophen and the possible consequences that could have on the welfare of US mothers and children."

On its online platform, Kenvue also mentioned it had "regularly reviewed the applicable studies and there is lacking reliable evidence that shows a established connection between using paracetamol and autism."

Associations speaking for doctors and healthcare providers concur.

ACOG has said acetaminophen - the key substance in Tylenol - is among limited choices for expectant mothers to treat discomfort and fever, which can create significant medical dangers if left untreated.

"In multiple decades of research on the consumption of acetaminophen in pregnancy, no reliable research has conclusively proven that the usage of acetaminophen in any trimester of pregnancy causes brain development issues in young ones," the group stated.

The court filing cites recent announcements from the former administration in asserting the drug is allegedly unsafe.

In recent weeks, the former president raised alarms from health experts when he told women during pregnancy to "resist strongly" not to take Tylenol when sick.

Federal regulators then published an announcement that medical professionals should think about restricting the usage of Tylenol, while also declaring that "a direct connection" between the drug and autism in children has not been proven.

Health Secretary Robert F Kennedy Jr, who manages the FDA, had pledged in April to conduct "comprehensive study program" that would establish the cause of autism spectrum disorder in a limited time.

But specialists advised that identifying a single cause of autism - believed by scientists to be the result of a intricate combination of genetic and environmental factors - would be difficult.

Autism spectrum disorder is a type of lifelong neurodivergence and impairment that impacts how people perceive and relate to the surroundings, and is identified using physician assessments.

In his lawsuit, the attorney general - who supports Trump who is campaigning for the Senate - claims the manufacturer and J&J "deliberately disregarded and attempted to silence the evidence" around paracetamol and autism.

The lawsuit aims to force the firms "eliminate any commercial messaging" that states Tylenol is safe for women during pregnancy.

The Texas lawsuit mirrors the complaints of a collection of mothers and fathers of young ones with autism spectrum disorder and ADHD who filed suit against the producers of Tylenol in two years ago.

A federal judge threw out the lawsuit, declaring studies from the plaintiffs' authorities was inconclusive.

Mallory Bell
Mallory Bell

Elara is a science writer and astronomer with a passion for unraveling cosmic mysteries and sharing insights with readers worldwide.